MED1 and cancer: Moreover, MED1 is implicated in the pathogenesis of various cancers, with studies demonstrating its overexpression in breast, liver, prostate cancer, and osteosarcoma [21–24], while its downregulation has been observed in colorectal, ovarian cancer, and bladder cancer [25, 26].